Answers are grounded in this paper and cite their sources.
HIV-1 group M subtypes A and B differ substantially in their gp120 sequence. To determine whether these differences contribute to subtype-specific complications, particularly pulmonary arterial hypertension (PAH), rats were injected with gp120 from subtype A or B. Pulmonary artery (PA) remodeling was assessed after four weeks using hematoxylin and eosin (H&E) staining and the Vessel Morphometry Analysis tool by Autona (autona.org). Subtype A gp120 potently increased PA wall thickness and right ventricular hypertrophy. The CD4-binding region of subtype A lacks a stretch of 16 amino acids (V1 N-glycosylation site), and experiments showed stronger binding of subtype B to CD4. Subtype B gp120 contains an RGKV sequence, which resembles the RGKR sequence of the rabies virus glycoprotein G that binds to the nicotinic acetylcholine receptor (nAChR). Subtype A gp120 possesses a KDKK sequence instead. Molecular dynamics simulations indicated that both sites are surface-exposed. Although nAChR is expressed in PA cells and could potentially drive the pronounced effects of subtype A, MD simulations estimated that subtype B gp120 binds more strongly to nAChR. We also noted a single amino acid difference immediately preceding the REKR furin cleavage sequence: glutamate in subtype A versus glutamine in subtype B gp120. Simulations predicted that subtype A gp120 interacts more effectively with furin, and enzyme assays demonstrated that subtype A promotes a positive feedback loop more strongly than subtype B. Thus, HIV-1 gp120 subtype A is more potent in promoting PAH, and the mechanism may involve enhancing furin activity to elevate gp120 levels.
No takes yet. Share an insight, caveat, or question.
Tamazawa et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: